title: Cyclosporine Neoral in liver transplant recipients.
authors.affiliation: Toronto Hospital-University of Toronto, Ontario, Canada.
authors.forename: G
authors.initials: G
authors.lastname: Levy
authors.forename: J
authors.initials: J
authors.lastname: Rochon
authors.forename: D
authors.initials: D
authors.lastname: Freeman
authors.forename: P Y
authors.initials: PY
authors.lastname: Wong
authors.forename: L
authors.initials: L
authors.lastname: Banks
authors.forename: C
authors.initials: C
authors.lastname: Roach
authors.forename: K
authors.initials: K
authors.lastname: Engel
authors.forename: D
authors.initials: D
authors.lastname: Grant
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002779:Cholestasis / Q000150:complications*; D016572:Cyclosporine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007408:Intestinal Absorption; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D008657:Metabolic Clearance Rate; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011183:Postoperative Complications
chemical_list: D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D016572:Cyclosporine; D008775:Methylprednisolone